July 21, 2021 10:35 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today ...
Biotech leader joins team as company evolves investigational UNITE platform and advances business July 19, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical ...
April 27, 2021 12:00 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021. ...
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy
Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Immunomic Therapeutics, ...
February 02, 2021 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the BIO ...
January 05, 2021 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13th Annual ...
ITI Executives and Board Members of WhyWeVax™ Discuss COVID-19 Vaccine Issues with Fox News and CDC’s ACIP Committee
December 09, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax™ (WWV), ...
December 01, 2020 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit. ...
November 19, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, ...
-Data from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice- November 02, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, ...
Oct. 22, 2020 12:00 UTC Immunomic Therapeutics Announces Promotion of Dr. Tim Coleman to Senior Vice President, Operations and General Manager ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately-held ...
10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health Immunomic Therapeutics is listed as one of the Top 10 Maryland Vaccine Influencers in public health and Dr. ...